Overview

A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases.

Status:
Not yet recruiting

Trial end date:
2022-01-30

Target enrollment:

Participant gender:

Summary

The study is being conducted to assess the effectiveness and safety of treatment options for breast cancer brain metastases based on molecular typing.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Bevacizumab
Carboplatin
Cisplatin
Temozolomide